Effect of response to interferon-α therapy on the occurrence of hepatocellular carcinoma in patients with chronic hepatitis B

Digestive Diseases

Volumn 30, Issue 6, 2012, Pages 568-573

  Lee, Danbi ^a   Chung, Young Hwa ^a   Lee, Sae Hwan ^b   Kim, Sung Eun ^a   Lee, Yoon Seon ^a   Kim, Kang Mo ^a   Lim, Young Suk ^a   Lee, Han Chu ^a   Lee, Yung Sang ^a   Yu, Eunsil ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Soonchunhyang University College of Medicine   (South Korea)

Author keywords

Biochemical response; Chronic hepatitis B; Hepatocellular carcinoma; Interferon

Indexed keywords

ALBINTERFERON ALPHA2B; ALPHA FETOPROTEIN; HEPATITIS B(E) ANTIGEN; RECOMBINANT ALPHA2B INTERFERON; VIRUS DNA;

ADULT; AGE; ALCOHOL ABUSE; CANCER GROWTH; CANCER INCIDENCE; CANCER RISK; CANCER SUSCEPTIBILITY; CONFERENCE PAPER; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEROCONVERSION; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGE FACTORS; ALPHA-FETOPROTEINS; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYETHYLENE GLYCOLS; PROPORTIONAL HAZARDS MODELS; RECOMBINANT PROTEINS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84871835548     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000343068     Document Type: Conference Paper

References (31)

1. Van Zonneveld M, Honkoop P, Hansen BE, Niesters HG, Murad SD, de Man RA, Schalm SW, Janssen HL: Long-term follow-up of -interferon treatment of patients with chronic hepatitis B. Hepatology 2004; 39: 804-810. (Pubitemid 38337661)
2. Kim DY, Han KH: Epidemiology and surveillance of hepatocellular carcinoma. Liver Cancer 2012; 1: 2-14.
3. Lok AS: Chronic hepatitis B. N Engl J Med 2002; 346: 1682-1683.
4. Lok AS, McMahon BJ: Chronic hepatitis B. Hepatology 2007; 45: 507-539. (Pubitemid 46374607)
5. Osborn MK, Lok AS: Antiviral options for the treatment of chronic hepatitis B. J Antimicrob Chemother 2006; 57: 1030-1034. (Pubitemid 44644402)
6. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, Hsiao CK, Chen PJ, Chen DS, Chen CJ: Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347: 168-174. (Pubitemid 34764820)
7. Chung YH, Song IH, Song BC, Lee GC, Koh MS, Yoon HK, Lee YS, Sung KB, Suh DJ: Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon- for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis. Cancer 2000; 88: 1986-1991.
8. Dunk AA, Ikeda T, Pignatelli M, Thomas HC: Human lymphoblastoid interferon. In vitro and in vivo studies in hepatocellular carcinoma. J Hepatol1986; 2: 419-429. (Pubitemid 16086605)
9. Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF: Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999; 29: 971-975.
10. Yuen MF, Hui CK, Cheng CC, Wu CH, Lai YP, Lai CL: Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology 2001; 34: 139-145.
11. Yu E: Histologic grading and staging of chronic hepatitis: On the basis of standardized guideline proposed by the Korean Study Group for the Pathology of Digestive Diseases (in Korean). Taehan Kan Hakhoe Chi 2003; 9: 42-46.
12. Bruix J, Sherman M: Management of hepatocellular carcinoma: An update. Hepatology 2011; 53: 1020-1022.
13. Nakaji M, Yano Y, Ninomiya T, Seo Y, Hamano K, Yoon S, Kasuga M, Teramoto T, Hayashi Y, Yokozaki H: IFN- prevents the growth of pre-neoplastic lesions and inhibits the development of hepatocellular carcinoma in the rat. Carcinogenesis 2004; 25: 389-397. (Pubitemid 38344406)
14. Papatheodoridis GV, Manesis E, Hadziyannis SJ: The long-term outcome of interferon- treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol 2001; 34: 306-313. (Pubitemid 32176454)
15. Lin SM, Yu ML, Lee CM, Chien RN, Sheen IS, Chu CM, Liaw YF: Interferon therapy in HBeAg-positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 2007; 46: 45-52.
16. International Interferon- Hepatocellular Carcinoma Study Group: Effect of interferon- on progression of cirrhosis to hepatocellular carcinoma: A retrospective cohort study. Lancet 1998; 351: 1535-1539.
17. Ikeda K, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, Fukuda M, Koida I, Arase Y, Chayama K, Murashima N, et al: Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: A pilot study. Cancer 1998; 82: 827-835. (Pubitemid 28104160)
18. Lampertico P, Del Ninno E, Vigano M, Romeo R, Donato MF, Sablon E, Morabito A, Colombo M: Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology 2003; 37: 756-763. (Pubitemid 36397385)
19. Craxi A, Di Bona D, Camma C: Interferon- for HBeAg-positive chronic hepatitis B. J Hepatol 2003; 39(suppl 1):S99-S105.
20. Hoofnagle JH, Peters M, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Hallahan C, Park Y, Meschievitz C, Jones EA: Randomized, controlled trial of recombinant human -interferon in patients with chronic hepatitis B. Gastroenterology 1988; 95: 1318-1325.
21. Brook MG, Karayiannis P, Thomas HC: Which patients with chronic hepatitis B virus infection will respond to -interferon therapy? A statistical analysis of predictive factors. Hepatology 1989; 10: 761-763. (Pubitemid 19270158)
22. Perrillo RP, Schiff ER, Davis GL, Bodenheimer HC Jr, Lindsay K, Payne J, Dienstag JL, O'Brien C, Tamburro C, Jacobson IM, et al: A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med 1990; 323: 295-301. (Pubitemid 20237094)
23. Lok AS, Wu PC, Lai CL, Lau JY, Leung EK, Wong LS, Ma OC, Lauder IJ, Ng CP, Chung HT: A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 1992; 102: 2091-2097.
24. Park BK, Park YN, Ahn SH, Lee KS, Chon CY, Moon YM, Park C, Han KH: Long-term outcome of chronic hepatitis B based on histological grade and stage. J Gastroenterol Hepatol 2007; 22: 383-388. (Pubitemid 46238769)
25. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH: Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73. (Pubitemid 43042691)
26. Yim HJ, Lok AS: Natural history of chronic hepatitis B virus infection: What we knew in 1981 and what we know in 2005. Hepatology 2006; 43(suppl 1):S173-S181.
27. Tang B, Kruger WD, Chen G, Shen F, Lin WY, Mboup S, London WT, Evans AA: Hepatitis B viremia is associated with increased risk of hepatocellular carcinoma in chronic carriers. J Med Virol 2004; 72: 35-40. (Pubitemid 37484740)
28. Yu MW, Yeh SH, Chen PJ, Liaw YF, Lin CL, Liu CJ, Shih WL, Kao JH, Chen DS, Chen CJ: Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: A prospective study in men. J Natl Cancer Inst 2005; 97: 265-272.
29. Ohata K, Hamasaki K, Toriyama K, Ishikawa H, Nakao K, Eguchi K: High viral load is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Gastroenterol Hepatol 2004; 19: 670-675. (Pubitemid 38858201)
30. Van Zonneveld M, Zondervan PE, Cakaloglu Y, Simon C, Akarca US, So TM, Flink HJ, de Man RA, Schalm SW, Janssen HL: PEGinterferon improves liver histology in patients with HBeAg-positive chronic hepatitis B: No additional benefit of combination with lamivudine. Liver Int 2006; 26: 399-405.
31. Lang Z, Zhao C, Xu D: A prospective study on histological and serological changes after interferon- 2b treatment in patients with chronic hepatitis B infection (in Chinese). Zhonghua Gan Zang Bing Za Zhi 2001; 9: 145-147.